Idexx Laboratories, Inc [IDXX] stock is trading at $714.55, up 1.09%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IDXX shares have gain 4.72% over the last week, with a monthly amount glided 0.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Idexx Laboratories, Inc [NASDAQ: IDXX] stock has seen the most recent analyst activity on December 09, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $850. Previously, Stifel upgraded its rating to Buy on October 31, 2025, and kept the price target unchanged to $700. On October 01, 2025, UBS initiated with a Neutral rating and assigned a price target of $720 on the stock. BTIG Research reiterated its Buy rating and increased its price target to $785 on August 05, 2025. Jefferies initiated its recommendation with a Buy and recommended $625 as its price target on July 01, 2025. Leerink Partners started tracking with an Outperform rating for this stock on December 02, 2024, and assigned it a price target of $500. In a note dated July 25, 2024, BTIG Research initiated a Buy rating and provided a target price of $580 on this stock.
Idexx Laboratories, Inc [IDXX] stock has fluctuated between $356.14 and $769.98 over the past year. Currently, Wall Street analysts expect the stock to reach $803.57 within the next 12 months. Idexx Laboratories, Inc [NASDAQ: IDXX] shares were valued at $714.55 at the most recent close of the market. An investor can expect a potential return of 12.46% based on the average IDXX price forecast.
Analyzing the IDXX fundamentals
Idexx Laboratories, Inc [NASDAQ:IDXX] reported sales of 4.17B for the trailing twelve months, which represents a growth of 13.29%. Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.31%, and Net Profit Margin reading is 0.25%. To continue investigating profitability, this company’s Return on Assets is posted at 0.3, Equity is 0.68 and Total Capital is 0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.71.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 704.51 points at the first support level, and at 694.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 724.79, and for the 2nd resistance point, it is at 735.03.
Ratios To Look Out For
For context, Idexx Laboratories, Inc’s Current Ratio is 1.12. Further, the Quick Ratio stands at 0.81, while the Cash Ratio is 0.17. Considering the valuation of this stock, the price to sales ratio is 13.69, the price to book ratio is 36.62 and price to earnings (TTM) ratio is 56.64.
Transactions by insiders
Recent insider trading involved Hunt Nimrata, Executive Vice President, that happened on Nov 07 ’25 when 9425.0 shares were sold. Officer, NIMRATA K HUNT completed a deal on Nov 07 ’25 to buy 9425.0 shares. Meanwhile, Director SZOSTAK M ANNE sold 2187.0 shares on Aug 22 ’25.
